| 4Q 2025 total revenue grew 29% year-over-year to |
| 4Q 2025 net income of |
| Full-year 2025 total revenue grew 22% year-over-year to |
| Full-year 2025 net income of |
| Full-year 2025 adjusted EBITDA1 grew 127% year-over-year to |
| Three Months Ended | Year Ended | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Results | % Variance from Prior Year | Results | % Variance from Prior Year | ||||||||||||
| (In thousands unless otherwise noted) | Unaudited | Unaudited | |||||||||||||
| Number of completed Payor sessions | 449.7 | 36 | % | 1,617.0 | 32 | % | |||||||||
| Number of unique active Payor members | 124.1 | 30 | % | N/A | N/A | ||||||||||
| Total revenue | $ | 62,998 | 29 | % | $ | 228,871 | 22 | % | |||||||
| Total costs and operating expenses | $ | 59,169 | 23 | % | $ | 225,719 | 18 | % | |||||||
| Net income | $ | 4,765 | 293 | % | $ | 7,793 | 579 | % | |||||||
| Adjusted EBITDA (1) | $ | 6,566 | 147 | % | $ | 15,772 | 127 | % | |||||||
| Cash and cash equivalents at year-end | $ | 37,352 | — | $ | 37,352 | — | |||||||||
| Short-term marketable securities at year-end | $ | 55,234 | — | $ | 55,234 | — | |||||||||
| (1) | Adjusted EBITDA is a non-GAAP financial measure. For a definition of the measure and a reconciliation to the most directly comparable GAAP measure, see “Reconciliation of GAAP Results to Non-GAAP Results.” | ||||||||||||||
Dr.
Fourth Quarter 2025 Key Performance Metrics
- Revenue increased 29% over the prior-year period to
$63.0 million , driven by a 41% year-over-year increase in Payor revenue, partially offset by a 30% year-over-year decline in Consumer revenue. - Cost of revenue, excluding depreciation and amortization, increased 33% over the prior-year period to
$36.1 million , driven by a higher number of completed Payor sessions. - Total costs and operating expenses were
$59.2 million , an increase of 23% year-over-year, primarily due to an increase in cost of revenue, excluding depreciation and amortization. - Net income was
$4.8 million , an increase of 293% over the prior-year period, primarily driven by an increase in revenue, partially offset by an increase in cost of revenue, excluding depreciation and amortization. - Adjusted EBITDA was
$6.6 million , an improvement from$2.7 million adjusted EBITDA in the fourth quarter of 2024, primarily driven by an increase in revenue, partially offset by an increase in cost of revenue, excluding depreciation and amortization.
Full Year 2025 Key Performance Metrics
- Revenue increased 22% over the prior-year to
$228.9 million , driven by a 38% year-over-year increase in Payor revenue, partially offset by a 30% year-over-year decline in Consumer revenue. - Cost of revenue, excluding depreciation and amortization, increased 29% over the prior-year to
$130.5 million , driven by a higher number of completed Payor sessions. - Total costs and operating expenses were
$225.7 million , an increase of 18% year-over-year, primarily due to an increase in cost of revenue, excluding depreciation and amortization. - Net income was
$7.8 million , an increase of 579% over the prior-year, primarily driven by an increase in revenue, partially offset by an increase in cost of revenue, excluding depreciation and amortization. - Adjusted EBITDA was
$15.8 million , an improvement from$7.0 million adjusted EBITDA in 2024, primarily driven by an increase in revenue, partially offset by an increase in cost of revenue, excluding depreciation and amortization.
Financial Guidance
The following guidance is based on current market conditions and expectations, and the information available to the Company today. For 2026
- Revenue to be in the range of
$275 million to$290 million - Adjusted EBITDA to be in the range of
$30 million to$35 million
Conference Call, Presentation Slides, and Webcast Details
The Fourth Quarter 2025 earnings conference call and webcast will be held
About
All care offered at
For more information, visit www.talkspace.com.
For Investors:
ICR Westwicke
TalkspaceIR@westwicke.com
For Media:
press@talkspace.com
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking, including statements regarding our financial condition, anticipated financial performance, business strategy and plans, market opportunity and expansion and objectives of our management for future operations. These forward-looking statements generally are identified by the words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “opportunity,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strategy,” “strive,” “target,” “will,” or “would,” the negative of these words or other similar terms or expressions. The absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many important factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) rapid technological change in our industry; (ii) our ability to secure clients' contract renewals; (iii) our ability to maintain and expand our network of therapists, psychiatrists and other providers; (iv) a decline in the prevalence of enterprise-sponsored healthcare or the emergence of new technologies may adversely impact our DTE business; (v) if our or our vendors’ security measures fail or are breached; (vi) changes in healthcare laws, regulations or trends and our ability to operate in the heavily regulated healthcare industry; and (vii) the other factors, risks and uncertainties described under the caption “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on
Consolidated Income Statements | ||||||||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||||||||
| 2025 | 2024 | % Change | 2025 | 2024 | % Change | |||||||||||||||||
| (in thousands, except percentages, share and per share data) | Unaudited | Unaudited | Unaudited | |||||||||||||||||||
| Revenue: | ||||||||||||||||||||||
| Payor revenue | $ | 47,663 | $ | 33,847 | 40.8 | $ | 171,518 | $ | 124,339 | 37.9 | ||||||||||||
| DTE revenue | 11,634 | 9,555 | 21.8 | 39,880 | 38,466 | 3.7 | ||||||||||||||||
| Consumer revenue | 3,701 | 5,318 | (30.4 | ) | 17,473 | 24,788 | (29.5 | ) | ||||||||||||||
| Total revenue | 62,998 | 48,720 | 29.3 | 228,871 | 187,593 | 22.0 | ||||||||||||||||
| Costs and operating expenses: | ||||||||||||||||||||||
| Cost of revenue, excluding depreciation and amortization | 36,075 | 27,075 | 33.2 | 130,522 | 101,311 | 28.8 | ||||||||||||||||
| Research and development | 2,357 | 2,232 | 5.6 | 9,544 | 10,280 | (7.2 | ) | |||||||||||||||
| Clinical operations, net | 1,793 | 1,740 | 3.0 | 7,208 | 6,542 | 10.2 | ||||||||||||||||
| Sales and marketing | 12,380 | 11,990 | 3.3 | 53,803 | 50,525 | 6.5 | ||||||||||||||||
| General and administrative | 5,743 | 4,907 | 17.0 | 21,767 | 22,573 | (3.6 | ) | |||||||||||||||
| Depreciation and amortization | 821 | 207 | 296.6 | 2,875 | 859 | 234.7 | ||||||||||||||||
| Total costs and operating expenses | 59,169 | 48,151 | 22.9 | 225,719 | 192,090 | 17.5 | ||||||||||||||||
| Income (loss) from operations | 3,829 | 569 | 572.9 | 3,152 | (4,497 | ) | * | |||||||||||||||
| Financial income, net | (1,286 | ) | (616 | ) | 108.8 | (5,215 | ) | (5,739 | ) | (9.1 | ) | |||||||||||
| Income before income taxes | 5,115 | 1,185 | 331.6 | 8,367 | 1,242 | 573.7 | ||||||||||||||||
| Income tax expense (benefit) | 350 | (29 | ) | * | 574 | 94 | 510.6 | |||||||||||||||
| Net income | $ | 4,765 | $ | 1,214 | 292.5 | $ | 7,793 | $ | 1,148 | 578.8 | ||||||||||||
| Net income per share: | ||||||||||||||||||||||
| Basic | $ | 0.03 | $ | 0.01 | 200.0 | $ | 0.05 | $ | 0.01 | 400.0 | ||||||||||||
| Diluted | $ | 0.03 | $ | 0.01 | 200.0 | $ | 0.04 | $ | 0.01 | 300.0 | ||||||||||||
| Weighted average shares used to compute net income per share: | ||||||||||||||||||||||
| Basic | 166,001,374 | 169,202,561 | 167,089,060 | 168,906,900 | ||||||||||||||||||
| Diluted | 171,866,106 | 176,711,336 | 173,648,431 | 176,495,872 | ||||||||||||||||||
| * Percentage not meaningful. | ||||||||||||||||||||||
Consolidated Statements of Comprehensive Income | |||||||||||||||||
| Three Months Ended | Year Ended | ||||||||||||||||
| 2025 | 2024 | % Change | 2025 | 2024 | % Change | ||||||||||||
| (in thousands) | Unaudited | Unaudited | Unaudited | ||||||||||||||
| Net income | $ | 4,765 | $ | 1,214 | 292.5 | $ | 7,793 | $ | 1,148 | 578.8 | |||||||
| Other comprehensive income (loss): | |||||||||||||||||
| Change in unrealized gain (loss) on marketable debt securities | (4 | ) | 2 | * | 55 | 2 | * | ||||||||||
| Total other comprehensive income (loss) | (4 | ) | 2 | * | 55 | 2 | * | ||||||||||
| Total comprehensive income | $ | 4,761 | $ | 1,216 | 291.5 | $ | 7,848 | $ | 1,150 | 582.4 | |||||||
| * Percentage not meaningful. | |||||||||||||||||
Consolidated Balance Sheets | ||||||||
| (in thousands) | Unaudited | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | 37,352 | $ | 76,692 | ||||
| Marketable securities | 55,234 | 41,118 | ||||||
| Accounts receivable, net | 16,061 | 9,643 | ||||||
| Other current assets | 2,415 | 2,729 | ||||||
| Total current assets | 111,062 | 130,182 | ||||||
| Fixed assets, net | 15,794 | 6,259 | ||||||
| 3,318 | — | |||||||
| Other long-term assets | 4,689 | 2,236 | ||||||
| Total assets | $ | 134,863 | $ | 138,677 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Accounts payable | $ | 8,501 | $ | 7,710 | ||||
| Accrued expenses and other current liabilities | 6,672 | 8,031 | ||||||
| Deferred revenue | 2,223 | 3,282 | ||||||
| Total current liabilities | 17,396 | 19,023 | ||||||
| Other long-term liabilities | 452 | 2,259 | ||||||
| Total liabilities | 17,848 | 21,282 | ||||||
| STOCKHOLDERS’ EQUITY: | ||||||||
| Common stock | 17 | 17 | ||||||
| Additional paid-in capital | 378,384 | 386,612 | ||||||
| Accumulated deficit | (261,443 | ) | (269,236 | ) | ||||
| Accumulated other comprehensive income | 57 | 2 | ||||||
| Total stockholders’ equity | 117,015 | 117,395 | ||||||
| Total liabilities and stockholders’ equity | $ | 134,863 | $ | 138,677 | ||||
Consolidated Statements of Cash Flows | ||||||||
| Year Ended | ||||||||
| 2025 | 2024 | |||||||
| (in thousands) | Unaudited | |||||||
| Cash flows from operating activities: | ||||||||
| Net income | $ | 7,793 | $ | 1,148 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 2,875 | 859 | ||||||
| Accretion of discount on marketable securities | (856 | ) | (417 | ) | ||||
| Stock-based compensation | 8,445 | 9,173 | ||||||
| Remeasurement of warrant liabilities | (1,491 | ) | (152 | ) | ||||
| (Increase) decrease in accounts receivable, net | (6,418 | ) | 531 | |||||
| Decrease in other current assets | 405 | 2,989 | ||||||
| Increase in accounts payable | 791 | 1,599 | ||||||
| (Decrease) increase in deferred revenue | (1,182 | ) | 213 | |||||
| Decrease in accrued expenses and other current liabilities | (1,644 | ) | (4,437 | ) | ||||
| Other | (184 | ) | (219 | ) | ||||
| Net cash provided by operating activities | 8,534 | 11,287 | ||||||
| Cash flows from investing activities: | ||||||||
| Purchases of marketable securities | (49,344 | ) | (40,701 | ) | ||||
| Proceeds from maturities of marketable securities | 36,084 | — | ||||||
| Capitalized internal-use software costs | (10,641 | ) | (5,443 | ) | ||||
| Acquisition of business, net of cash acquired | (4,904 | ) | — | |||||
| Other | (72 | ) | (171 | ) | ||||
| Net cash used in investing activities | (28,877 | ) | (46,315 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from exercise of stock options | 913 | 2,010 | ||||||
| Payments for employee taxes withheld related to vested stock-based awards | (2,707 | ) | (3,195 | ) | ||||
| Repurchase of common stock for retirement | (17,203 | ) | (11,003 | ) | ||||
| Net cash used in financing activities | (18,997 | ) | (12,188 | ) | ||||
| Net decrease in cash and cash equivalents | (39,340 | ) | (47,216 | ) | ||||
| Cash and cash equivalents at beginning of the year | 76,692 | 123,908 | ||||||
| Cash and cash equivalents at end of the year | $ | 37,352 | $ | 76,692 | ||||
Non-GAAP Financial Measures
In addition to our financial results determined in accordance with GAAP, we believe adjusted EBITDA, a non-GAAP measure, is useful in evaluating our operating performance, and our management uses it as a key performance measure to assess our operating performance. Because adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes and in evaluating acquisition opportunities. We also use adjusted EBITDA to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that this non-GAAP financial measure, when taken together with the corresponding GAAP financial measures, provides meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations or outlook. We believe that the use of adjusted EBITDA is helpful to our investors as it is a metric used by management in assessing the health of our business and our operating performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP.
Some of the limitations of adjusted EBITDA include (i) adjusted EBITDA does not necessarily reflect capital commitments to be paid in the future and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and adjusted EBITDA does not reflect these requirements. In evaluating adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments described herein. Our presentation of adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. Our adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate adjusted EBITDA in the same manner as we calculate the measure, limiting its usefulness as a comparative measure. Adjusted EBITDA should not be considered as an alternative to income (loss) before income taxes, net income (loss), income (loss) per share, or any other performance measures derived in accordance with
A reconciliation is provided below for adjusted EBITDA to net income, the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review our financial statements prepared in accordance with GAAP and the reconciliation of our non-GAAP financial measure to its most directly comparable GAAP financial measure, and not to rely on any single financial measure to evaluate our business. We do not provide a forward-looking reconciliation of adjusted EBITDA guidance as the amount and significance of the reconciling items required to develop meaningful comparable GAAP financial measures cannot be estimated at this time without unreasonable efforts. These reconciling items could be meaningful.
Adjusted EBITDA
We calculate adjusted EBITDA as net income adjusted to exclude (i) depreciation and amortization, (ii) stock-based compensation expense, (iii) financial income, net, (iv) income tax expense (benefit), and (v) certain non-recurring expenses, where applicable.
Reconciliation of GAAP Results to Non-GAAP Results | |||||||||||||||||
| (Unaudited) | |||||||||||||||||
| Three Months Ended | Year Ended | ||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||
| (in thousands) | |||||||||||||||||
| Net income | $ | 4,765 | $ | 1,214 | $ | 7,793 | $ | 1,148 | |||||||||
| Add: | |||||||||||||||||
| Depreciation and amortization | 821 | 207 | 2,875 | 859 | |||||||||||||
| Stock-based compensation | 1,916 | 1,883 | 8,445 | 9,173 | |||||||||||||
| Financial income, net | (1,286 | ) | (616 | ) | (5,215 | ) | (5,739 | ) | |||||||||
| Income tax expense (benefit) | 350 | (29 | ) | 574 | 94 | ||||||||||||
| Non-recurring expenses (1) | — | — | 1,300 | 1,427 | |||||||||||||
| Adjusted EBITDA | $ | 6,566 | $ | 2,659 | $ | 15,772 | $ | 6,962 | |||||||||
| (1) | For the year-ended | ||||||||||||||||
Source: